Cellectis (ADR) (CLLS)
Develops gene-edited allogeneic CAR-T candidates and manufacturing capabilities.
Something off on this page? Send us feedback.
Develops donor-derived UCART cell-therapy candidates for blood cancers and applies its TALEN platform in an AstraZeneca collaboration. Its disclosed proprietary focus is lasme-cel for B-cell acute lymphoblastic leukemia and eti-cel for non-Hodgkin lymphoma.
Gene-edits donor-derived T cells into allogeneic UCART candidates for immuno-oncology, supported by TALEN®/nuclease technologies and manufacturing capabilities. The proprietary clinical focus is lasme-cel for relapsed or refractory B-cell acute lymphoblastic leukemia and eti-cel for relapsed or refractory non-Hodgkin lymphoma.
Operations span Paris, New York, and Raleigh, with Paris producing starting materials and Raleigh handling UCART clinical and commercial manufacturing and release testing. Most of the workforce has been in research and development.
Clinical and regulatory progress for lasme-cel and eti-cel shapes the business, alongside the AstraZeneca collaboration, which uses its editing expertise and manufacturing capabilities across oncology, immunology, and rare genetic diseases.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 16, 2026 | Barclays | Downgrade | Target: $9 | Target: $1.30 |
| Sep 15, 2026 | Wells Fargo | Reiterate | Rating: —Target: $4 | Target: $3 |
| Sep 15, 2026 | Citigroup | Downgrade | ||
| Sep 15, 2026 | Citizens | Downgrade | ||
| May 28, 2026 | Barclays | Target | Target: $8 | Target: $9 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $166.8M · Total debt $84.6M · Total assets $267.4M · Shareholders' equity $41.1M
- Revenue
- $5.2M
- Operating income
- −$25.5M
- Net income
- −$21.8M
No dividends on record.
| Institutions | 9.44% | 9.48M ADS | |
|---|---|---|---|
| 27 holders · as of Jun 30, 2026 | |||
| Insiders | 10.56% | 10.60M ADS | |
| 1 holder · as of Dec 12, 2025 | |||
| Other | 80.00% | 80.34M ADS | |
| remainder | |||
100.42M ADS as of Aug 27, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (72.34M in the company's Sep 22, 2026 report, 100.42M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Caisse des DepotsInsider | 10.56% | 10.60M | filed Dec 12, 2025 |
B Group, Inc.Institution | 3.27% | 3.28M ADS | as of Jun 30, 2026 |
Long Focus Capital Management, LLCInstitution | 2.73% | 2.74M ADS | as of Jun 30, 2026 |
UBS Asset Management Americas IncInstitution | 2.63% | 2.64M ADS | as of Jun 30, 2026 |
Macquarie Management Holdings, Inc.Institution | 0.23% | 226,875 ADS | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Gilead Sciences
Marketed CD19 CAR-T options in adult B-ALL and B-cell lymphoma
- Autolus Therapeutics (ADR)
Approved CD19 CAR-T for adult relapsed/refractory B-cell precursor ALL
- Bristol-Myers Squibb
Marketed CD19 CAR-T for adult relapsed/refractory large B-cell lymphoma
- Novartis (ADR)
Approved CD19 CAR-T in B-ALL and relapsed/refractory B-cell lymphoma
- Caribou Biosciences
Allogeneic CD19 CAR-T in clinical development for r/r B-cell NHL
- CRISPR Therapeutics
Allogeneic CD19 CAR-T in clinical development for r/r B-cell lymphomas
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cellectis (ADR) | $1.57 | +3.97% | $151.6M | — | — | 2.7 | −59.2% |
| Gilead Sciences | $152.57 | +1.33% | $186.93B | — | 16.8 | 6.1 | +10.2% |
| Autolus Therapeutics (ADR) | $2.05 | +5.41% | $516.3M | — | — | 4.4 | +118.4% |
| Bristol-Myers Squibb | $62.53 | −0.14% | $127.91B | 13.8 | 9.8 | 2.6 | +5.7% |
| Novartis (ADR) | $141.27 | +0.21% | $267.96B | 21.3 | 15.0 | 4.8 | +0.9% |
| Caribou Biosciences | $1.34 | +3.08% | $128.9M | — | — | 12.8 | −43.8% |
| CRISPR Therapeutics | $58.26 | −0.11% | $5.63B | — | — | 420.1 | +1,041.4% |
| Median | 17.5 | 15.0 | 5.5 | +8.0% |